The U.S. Food and Drug Administration (FDA) has reported the successful achievement of its first-year objectives aimed at reducing animal testing in drug development, representing a notable milestone for the in silico medicine community.
Discover the recently published papers from our community!
Discover the recently published papers from our community!
The VPH Society is preparing to contribute to the upcoming HORIZON-MISS-2026-02-CANCER-01 call under the European Commission Mission on Cancer, and invites interested organisations to get in touch for collaboration.
Over the past months, VPH has been actively involved in a number of project proposals, confirming its role as a trusted partner for high-impact, cross-cutting activities.
The VPH Best Poster Award honours the best poster presentation by a VPH student member at the VPH 2026 Conference. The winner will receive a certificate and a €350 cash prize.
On 18 March 2026, the Food and Drug Administration (FDA) published a new draft guidance titled "General Considerations for the Use of New Approach Methodologies in Drug Development", marking a significant step toward integrating innovative, non-animal methodologies into regulatory decision-making.
On 9 March 2026, the European Medicines Agency (EMA) published the Network Data Steering Group (NDSG) Workplan 2026–2028 outlining a strategic roadmap for strengthening the use of data and AI across the European medicines regulatory network.
REALM- the R&I consortium that VPH is part of- recently participated in the MetReal Multistakeholder Meeting that took place in Copenhagen on 2-3 March 2026.
The upcoming VPH Conference is just around the corner, and we are pleased to remind all members that they can benefit from exclusive discounted registration fees.
Highlights from the REALM Patient Group Workshop on safety, trust, and real-world impact.
How a failing device implanted in 1958 set in motion a revolution that is now restoring speech, movement, and vision through electronics wired directly to the brain.
